
    
      Part 1 is a randomized, double-maskedtrial trial designed to investigate the use of TLC399 in
      subjects with macular edema due to CRVO or BRVO. Three different dose strengths will be
      evaluated.

      Part 2 is a randomized, double-masked study designed to evaluate 2 doses of TLC399 in
      subjects with macular edema due to CRVO or BRVO. Subjects will be randomized 1:1 to receive
      two different dose strenghs of investigational product.
    
  